Abstract
Most of these pharmacological agents have been designed and/or developed based upon a notion that has been dominating the AD field for the past two decades -the 'amyloid cascade hypothesis'. This theory claims that the metabolism of the amyloid-␤ (A␤) peptide (both generation and clearance) is the main initiator of AD, which together with the downstream formation of the -protein aggregates, leads to neuronal and synaptic dysfunction and loss, microglial activation and neuronal death
. Thus, most of the pharma-cological agents being developed target one or both of the principal cerebral proteins implicated in the pathogenesis of AD: and A␤. In this review, we will provide a broad overview of the therapeutic approaches currently being developed for the treatment of AD.
AD pharmacotherapies targeting
Neurofibrillary tangles (NFTs) , which are found in AD and other forms of dementia, consist of insoluble, intra-neuronal inclusions [22, 23] comprised paired helical filaments that are formed from hyperphosphorylated [24, 25] . Hyperphosphorylation of the microtubule-associated -protein is likely to result from an imbalance in kinase and phosphatases activities, and leads to destabilization of microtubules [26] , loss of neuronal cytoskeletal architecture and/or plasticity [27] , impaired neuronal transport, dystrophy and ultimately neuronal cell death [28, 29] . Based on these findings, small molecules that interfere with the formation of -aggregates, selectively inhibit -kinases and/or activate -phosphatases are being pursued as therapeutic targets (see Fig. 1 ).
Modulators of kinases or phosphatases
The biological function of the microtubule-associated -protein [30] is regulated by several kinases and phosphatases [31] [32] [33] 
have highlighted the importance of GSK-3␤ in the developments of both and A␤ pathologies in AD and concluded that this kinase is a vital drug target for the treatment of AD and other neurodegenerative diseases [54-57]. Several animal studies, for example, have demonstrated that the inhibition of GSK-3␤ activity by lithium [58] results in decreased levels of both A␤ (in PDAPP mice) and -phospho-rylation, -aggregation and NFT formation (in JNPL3 mutant

aggregation inhibitors (TAIs)
Screening for TAIs started in the early 1990s with reports on the ability of phenothiazines [71], anthraquinones [72] and low molecular weight N-phenylamine derivatives [73] to prevent -aggregation and associated toxicity in cell lines [74]. The most clinically advanced TAI is AL-108 or NAP (Allon Therapeutics Inc., Vancouver, BC, Canada), which is an intra-nasal formulation of an 8 amino-acid peptide (NAPVSIPQ) derived from the biological activity-dependent neuroprotective protein secreted by the brain in response to various insults [75]. Studies in transgenic mice suggest that AL-108 interacts with microtubules, reduces -hyperphosphorylation and increases soluble levels leading to an improvement in cognition [76, 77]. Data from a recently completed phase IIa trial evaluating AL-108 in 144 patients with amnestic mild cognitive impairment demonstrated that it is safe and well tolerated, and the high dose (15 mg twice a day) resulted in a significant and lasting improvement in short term and working memory (but not in tests that involved executive functions). AL-108 is now being tested as a treatment for other neurodegenerative diseases, mental disorders and ocular disease. An intravenous (IV) formulation of NAP, known as AL-208, is also under clinical investigation for mild cognitive impairment associated with coronary artery bypass graft surgery as well as other indications [78].
A recently announced TAI is Rember™ (TauRx Therapeutics Ltd., Singapore), which has methylthioninium chloride (MTC; also known as the histochemical dye methylene blue) as its active constituent. It is proposed that this compound is not only able to prevent the oligomerization and self-aggregation of , but also dissolve pre-formed -oligomers and paired helical filaments into truncated 
AD pharmacotherapies targeting A␤
Although the exact mechanism is still unclear, it is widely believed that dysfunctional A␤ metabolism is the underlying cause for the neurodegeneration and dementia observed in AD. Therefore, a leading strategy for the development of AD pharmacotherapies is modulation of A␤ production, aggregation and/or clearance. It is assumed that altering these processes will stop and/or reverse the pathological neuronal loss and the clinical cognitive decline. We will briefly summarize key findings of the major AD pharmacological strategies being development to target various aspects of A␤ metabolism (see Fig. 2 ). [168] are more neurotoxic than the mature A␤ fibrils [169] [170] [171] [172] [173] . Indeed, the severity of AD correlates more closely with cerebral concentrations of soluble A␤ rather than insoluble A␤ load (reviewed by Lesne and Kotilinek [174] ). As our understanding of A␤ structure improves and with the advent of more advanced techniques, the development of inhibitors of A␤ oligomers will improve [175] . Candidate drugs in this category are synthetic peptides based on the A␤17-21 sequence, with the fiveamino-acid ␤-sheet breaker peptide Ac-LPFFD-NH2 (iA␤5p) as its lead compound [176, 177] [185, 186] . Activation of microglia and inflammatory factors [187] and induction of apoptosis by A␤-mediated activation of cysteine aspartyl proteases termed caspases [114, 188, 189] 
Inhibitors and/or modulators of the secretases
have also been proposed to have neurotoxic effects. Berman and colleagues recently demonstrated that A␤ oligomer-induced neurotoxicity is due to the destabilization of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2)
metabolism [190] . Another proposed mechanism of A␤ toxicity is the promotion of ion-channel formation and calcium ion (Ca 2ϩ ) influx [191] [192] [193] [194] [195] . However, metaanalysis of clinical studies revealed that nimodipine only slows down the disease progression and may be effective only in certain types of dementia [196] .
As for MEM 1003, late last year Memory Pharmaceuticals announced that the drug failed to show changes in ADAS-Cog scores between treated and control mild-to-moderate AD patients in a phase IIa trial, yet the company is still testing the efficacy of MEM 1003 in individuals with bipolar disorder (www.memorypharma.com).
Passive or active immunization
A novel and controversial approach to treating AD is based on vaccine therapy. Transgenic mouse models of AD actively immunized with A␤ [197] [198] [199] [200] or passively immunized with humanized anti-A␤ antibodies [201] [202] [203] [204] [205] [206] [207] [208] ) have also been shown to induce A␤ precipitation [227, 230, [260] [261] [262] . These data suggest that the synaptic cleft is an ideal location for A␤ metallation and aggregation, as neurotransmission results in peak concentrations of ~300 M Zn 2ϩ [263, 264] and up to 100 M Cu 2ϩ [265] [266] [267] . This is sup- ) [268, 269] , which is responsible for zinc enrichment and transport into pre-synaptic vesicles [270, 271] [293, 303, 304] and therefore do not allow metal-induced A␤ aggregation in vitro [256, 260] and cerebral A␤ deposits in vivo [305] .
In summary, the above findings demonstrate APP and/or A␤ play a major physiological role in regulating metal-ion levels. This cumulative data has lead Bush, Tanzi and colleagues to propose 'the metal theory of AD' [306] , which stipulates that age-related endogenous metal dyshomeostasis in the brain allows binding of [307] [308] [309] , induces the covalent di-tyrosine crosslink of A␤ [274, 286, 287, [310] [311] [312] [313] [314] [315] [316] [317] and promotes the generation of SDS-resistant copper-derived diffusible ligands [278, 286, 316] . Metallated-A␤ also has an increased affinity for the phospholipid heads of the membrane bilayer [318, 319] 
AD pharmacotherapies targeting metal ions
The equilibrium (concentrations, distribution, stability and bioavailability) of metal ions is critical for many physiological functions. This is particularly true for the CNS, where metals are essential for development and maintenance of enzymatic activities, mitochondrial function [327, 328] , myelination [329] , neurotransmission [330] , learning and memory [331, 332] [333, 334] . [335] . Accordingly, modulation of metal ions has been proposed as a disease-modifying therapeutic strategy for AD [336] [337] [338] and other neurodegenerative diseases [339, 340] . Antioxidants and metal-modulators represent two such therapeutic strategies. [342, 343] and animal models [344] [345] [346] [347] [348] , but have had conflicting results in a clinical setting [349] [350] [351] .
Understanding the complex structural and functional interactions of metal ions with the various intracellular and extracellular components of the CNS, under normal conditions and during neurodegeneration, is essential for the development of effective therapies
Antioxidants
Antioxidant molecules are capable of neutralizing free or incorrectly bound metals, thereby interfering with the 'down-stream' generation of ROS and other radicals. Therefore, antioxidants may be used mainly as a preventative approach [341]. Numerous molecules with antioxidant properties, such as oestrogen, melatonin, vitamin C and E (L-ascorbate and ␣-topopherol, respectively), ginkgo bilboa extract, curcumin and flavonoids, have been shown to have neuroprotective effects against A␤-induced toxicity in cellbased experiments
Metal chelators
By definition, metal chelators bind strongly to two or more metal ions and form a cyclic ring, which converts the metal ions into an inert form and depletes the total pool of bioavailable metals. Desferrioxamine (DFO), an Fe chelator with high binding affinities for Zn, Cu and aluminium (Al) [352], was the first such agent to enter clinical investigations for the treatment of AD. Results of a 2-year-long, blinded phase II trial with a cohort of 48 AD patients demonstrated that 125 mg intramuscular injections twice daily for 5 days a week significantly slowed down the decline of some cognitive functions, compared to the two control arms (an oral placebo or no treatment) [353]. DFO, however, is a large hydrophilic molecule, which is not orally bio-available and does not normally penetrate the BBB. Hence, it is unknown whether the beneficial effect seen with the DFO treatment was due to the drug's interaction and/or chelation of metals, or due to a different mechanism all together [354]. Another hexadentate chelator, DP-109 (DPharm, Rehovot, Israel), is a large synthetic pro-drug that becomes activated following the cleavage of its two long-chain esters. Daily administration of DP-109 by oral gavage to female Tg2576 mice over a 3-month period reduced the formation and deposition of CAA and APs, as well as re-solubilized A␤ [355]. Like DFO, DP-109 is not expected to cross the BBB, therefore the way it exerts its anti-amyloidogenic effect is still not clear. Recently, DP-109 and DP-460 (another Ca, Cu and Zn lipophilic chelator) were reported to have neuroprotective effects in a G93A
transgenic mouse model of amyotrophic lateral sclerosis [356] , another neurodegenerative disease associated with metal imbalance [357, 358] . Other chelating agents have been reported to have different effects in vitro, including reduced A␤42-induced oxidative stress [359] , and the solubilization of hypophosphorylated [360] and A␤ from AD brain [361] . [372] [378, 379] . These properties are being exploited for its development as a radiotherapeutic agent [380] [381] [382] and as a radiopharmaceutical for positron emission tomography imaging [383, 384] . Cu [378, 385, 386] [390] [391] [392] [393] [394] [395] . CQ had been used as a therapeutic in cattle and human beings with Zn-deficiency diseases and for many decades was prescribed as an oral anti-amebic in addition to being used for the treatment of dysentery and diarrhoea [396, 397] . However, its oral preparation was withdrawn from the market during the 1960s to 1970s, as it was suspected to be involved in the development of subacute myelo-optico-neuropathy (SMON) [398] [399] [400] [401] . SMON is characterized by sensory and motor disorders in the lower limbs, peripheral neuropathy and visual impairment due to demyelation of the spinal cord, optic nerve and peripheral nerves [402] . SMON affected people worldwide; however, it reached near-epidemic proportions in Japan, where a few related deaths were reported [403] . At the time, a mechanistic link between CQ and SMON was not established [404] -mediated A␤ toxicity in neuronal cell culture [417] . Other studies, however, have suggested that CQ increases oxidative neurotoxicity [418] . As previously mentioned, CQ treatment caused a reduction in A␤ levels in CHO-APP cells, accompanied by increased phosphorylation of GSK-3 and MMP2/3 activity [225] . The 
Further in vivo studies with these chelators is required to further advance this therapeutic route and to rule out any systemic effects. An alternative approach to chelation is to modulate metals with metallo-complexes. Such an approach serves to remove metals from biologically deleterious sites and potentially deliver them to areas of deficiency, thereby maintaining overall metal homeostasis.
Metal complexes
Metallo-complexes are emerging as a new potential therapeutic for AD. The rational guiding this strategy is the delivery of Cu, for example, to cellular compartment which are Cu-deficient, using metallo-complexes of pyrrolidine dithiocarbamate (M 2ϩ -PDTC) or bis(thiosemicarbazone) (M 2ϩ -BTSC), or preventing the harmful binding of Cu to A␤, using platinum (Pt) complexed to 1,10 phenanthroline derivatives (L-PtCl2). PDTC is traditionally considered an inhibitor of the transcription-factor regulator nuclear factor-B (NF-B) with anti-inflammatory, antioxidant and anti-apoptotic properties [362-364] -all of which have been attributed to the synergistic interaction between PDTC, Cu and/or Zn [365-371]. As well as preventing the nuclear translocation of NF-B in a neonatal hypoxia-ischaemia model, PDTC also activates Akt and inhibits GSK-3␤
2ϩ -GTSM can also cross the BBB; however, once inside the cell it is reduced by various cellular reductants and releases its Cu molecule, which is made available for the cell
